Drug Profile
Research programme: respiratory disorders therapies - Kos Pharmaceuticals
Alternative Names: KI 03219; KI 04204Latest Information Update: 04 Mar 2008
Price :
$50
*
At a glance
- Originator Kos Pharmaceuticals
- Class
- Mechanism of Action Beta-adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 13 Dec 2006 Kos Pharmaceuticals has been acquired by Abbott Laboratories
- 25 Aug 2006 Preclinical trials in Asthma in USA (Inhalation)
- 25 Aug 2006 Preclinical trials in Chronic obstructive pulmonary disease in USA (Inhalation)